Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 10Breast Neoplasms 5Sarcoma 3Prostatic Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Castration Resistant Prostate Cancer 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Cancer Metastatic 1Advanced Solid Tumors 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

fluzoparib 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Platinum-sensitive Relapsed Ovarian Cancer × fluzoparib × Clear all
NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

The First Hospital of Jilin University

Phase 2 Not yet recruiting
22 enrolled
Gynecologic

Platinum-sensitive Relapsed Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡